Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study

by | Jan 1, 2020 | Publicaciones - CIMO-01 | 0 comments

Garcia-Munoz, R; Quero, C; Perez-Persona, E; Domingo-Garcia, A; Perez-Lopez, C; Villaescusa-de-la-Rosa, T; Martinez-Castro, AM; Arguinano-Perez, JM; Parra-Cuadrado, JF; Panizo, C – 2020